This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

14 Feb 2011

Novo Endeavors to Stay ahead in U.S. Market

Novo gave up the diabetes-pill business to focus on injectable insulins and now Novo insulin analogs have more competition.

How Novo Nordisk stole diabetes-drug market share from Eli Lilly and grew to $7.1 billion in insulin sales? You can check out the Forbes take-out on the Danish company to find out the answer. We'll just offer the short one here: Designer injectable insulin.


As Forbes notes, Novo got out of the diabetes-pill business to focus on injectable insulins. It went on to develop such new-and-improved insulin analogs as Novolog and Levimir, which it could sell for two to three times as much as older insulin m

Related News